Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week High – Should You Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares reached a new 52-week high on Monday . The company traded as high as $47.20 and last traded at $46.81, with a volume of 3469289 shares changing hands. The stock had previously closed at $44.95.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DFTX. Stifel Nicolaus set a $30.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Robert W. Baird boosted their price objective on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. JonesTrading lifted their target price on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $46.92.

Definium Therapeutics Trading Down 7.0%

The firm has a 50 day moving average of $25.56 and a 200 day moving average of $19.89. The firm has a market cap of $4.36 billion, a PE ratio of -17.56 and a beta of 2.37. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities analysts anticipate that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current year.

Insider Transactions at Definium Therapeutics

In related news, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the sale, the insider directly owned 174,633 shares in the company, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after purchasing an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Definium Therapeutics during the 3rd quarter valued at $107,000. Flagship Harbor Advisors LLC bought a new stake in shares of Definium Therapeutics during the 4th quarter valued at $117,000. Finally, Caxton Associates LLP purchased a new stake in Definium Therapeutics during the 3rd quarter worth about $126,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.